Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
By Hao Wu, E. Esteve, V. Tremaroli, M. Khan, Robert Caesar, L. Mannerås-Holm, M. Ståhlman, Lisa M. Olsson, M. Serino, Mercè Planas-Fèlix and 8 more. Nature Medicine, 2017
1,417 citations recorded by the source corpus.
Subfields: Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/41c95457abec8c7cdb1c28077ac7f0272c5893aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Gut Microbiome: Profound Implications for Diet and Disease (2019, background): “A four-month placebo-controlled study was recently performed on 40 newly diagnosed T2D patients [127].”
- Role of gut microbiota in type 2 diabetes pathophysiology (2020, background): “Potentially detrimental microbes in T2D (pathobionts), like Fusobacterium nucleatum and Ruminococcus gnavus can increase several inflammatory cytokines, albeit in other inflammatory diseases [103,104].”
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. (2018, background): “Administration of oxyntomodulin three times daily for 4 weeks to overweight or obese human subjects reduced food intake and induced weight loss (Wynne et al., 2005); oxyntomodulin also increased activity-related energy expenditure over a 4-day treatment period (Wynne et al., 2006).”
- Extensive impact of non-antibiotic drugs on human gut bacteria (2018, neutral): “…that more human-targeted drugs would interfere with bacterial growth if doses were to be increased towards drug-and body-site-specific concentrations. b. IC 25 ’s of metformin correlate well with its observed effects in humans 62, based on the four species that overlap between the two studies.”
- Cellular and Molecular Mechanisms of Metformin Action (2020, methodology): “Metformin has also been shown to have effects on peripheral glucose metabolism (3,43) and intestinal glucose metabolism (44,45), which are reviewed in the sections below.”
- NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “148 149 Similar to metformin, no robust RCT data exist with histological liver endpoints as a primary outcome to formally comment on the effectiveness of the use of the newer antihy-perglycaemic agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists…”